CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 

Cumulative Genocea Biosciences Inc 's Working Capital Ratio for Trailing Twelve Months Period

GNCA's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

GNCA Working Capital Ratio for Trailing Twelve Months Period

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Current Liabilities Growth 57.83 % -25.25 % -38.26 % -31.09 % -22.1 %
Y / Y Current Assets Growth -64.53 % -49.14 % -43.97 % 155.05 % 136.73 %
Working Capital Ratio for Trailing Twelve Months Period 2.71 3.76 4.01 4.05 3.25
Total Ranking # 2165 # 1646 # 1249 # 1163 # 1432
Seq. Current Liabilities Growth -3.5 % 27.06 % -0.86 % 29.83 % -54.29 %
Seq. Current Assets Growth -41.64 % -17.37 % -19.55 % -8.58 % -16.3 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2022
On the trailing twelve months basis Due to decrease in Current Liabilities in the I. Quarter to $18 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 2.71 below Genocea Biosciences Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 178 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Genocea Biosciences Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about GNCA
Working Capital Ratio GNCA in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 179
Sector # 1067
S&P 500 # 3784


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
13.47 4.37 2.32
(Dec 31 2016)   (Dec 31 2017)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Cognition Therapeutics inc   7.44 
Adaptimmune Therapeutics Plc  7.31 
Vectivbio Holding Ag  7.29 
Compugen Ltd  7.21 
X4 Pharmaceuticals Inc  7.21 
Ambrx Biopharma Inc   7.19 
Inhibrx Inc   7.12 
Biocardia Inc  7.05 
Gritstone Bio Inc   6.76 
Biomx Inc   6.71 
Axcella Health Inc   6.68 
Jasper Therapeutics Inc   6.55 
Pluri Inc   6.46 
Semper Paratus Acquisition Corporation  6.40 
Orchard Therapeutics Plc  6.39 
Codiak Biosciences Inc   6.35 
Cardiol Therapeutics inc   6.27 
Poseida Therapeutics Inc   6.25 
Palisade Bio Inc   6.20 
Seagen Inc   6.16 
Sqz Biotechnologies Company  6.14 
Exelixis Inc   6.12 
Vericel Corporation  6.07 
Aligos Therapeutics Inc   6.02 
Kaleido Biosciences Inc   6.00 
Kiromic Biopharma Inc   5.90 
Evaxion Biotech A  5.81 
Armata Pharmaceuticals Inc   5.69 
Denali Therapeutics Inc   5.64 
Beam Therapeutics Inc   5.59 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com